Please assess the completion status of the following clinical trial:

Trial Title: A Multinational Phase III Study of CS-8958 (MARVEL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of influenza~* Axillary temperature of \> or = to 37.5 degrees C~Exclusion Criteria:~* Infection by bacteria species and/or virus other than influenza virus~* Chronic respiratory disease~* Renal dysfunction

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-8958 Low Dose (Type: EXPERIMENTAL): CS-8958 powder to be inhaled - low-dose arm
- CS-8958 High Dose (Type: EXPERIMENTAL): CS-8958 powder to be inhaled - high-dose arm
- Oseltamivir phosphate (Type: ACTIVE_COMPARATOR): oseltamivir phosphate oral capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).